Endosopy AI | Eliminating blind spots | Global Distribution

**Executive Summary: Endovision** Standardizing Endoscopy Quality Control via Foundation AI Investment Opportunity Endovision is a Hong Kong-based MedTech startup solving the #1 challenge in upper-GI endoscopy: **clinical blind spots**. While competitors focus on commoditized polyp detection, Endovision provides a brand-agnostic software layer for real-time Quality Control (CAQ). Secured by a global distribution partnership with **Medtronic and Cosmo Pharma**, we are positioned as the essential software foundation for the next generation of endoscopy. The Clinical Challenge: The "Blind Spot" Risk * **Manual Inefficiency:** Manual EGD examinations routinely miss 22.5% of the mucosal surface due to operator cognitive and physical blind spots. * **Late Detection Mortality:** Missed diagnoses plummet survival rates from 95% to 6% at late stages. The Solution: Foundation, Not Replacement Our AI acts as a "second set of eyes," enforcing systematic quality control without disrupting clinical workflows. * **Brand-Agnostic Core:** Integrates with Olympus, Fujifilm, and Pentax systems via standard connection, serving as a neutral ecosystem hub. * **Proprietary Data Moat:** Built on a 30,000+ patient data asset—10x–20x larger than typical competitors. Commercial Strategy & Traction * **Global Scale:** Leveraging Medtronic’s 2,000+ existing GI-Genius install base for rapid EU expansion. * **Regulatory First-Mover:** CE/MDR Class IIa SaMD approval secured; FDA fast-track in progress (Expected Q2 2028). * **Business Model:** Recurring SaaS revenue ($1,000/month per system) with tiered royalty structures. The Ask: $1M Bridge Round (60% Committed) We are closing our final bridge round to accelerate clinical validation and market entry. * **FDA Submission:** Fast-tracking US market entry. * **EU Commercial Scaling:** Technical support and market access for Medtronic pipeline. * **Pipeline Expansion:** Finalizing EGC detection and auto-reporting modules.